Zacks Small Cap Research on MSN1h
RVPH: Year-End OLE UpdateRVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...
In terms of pipeline development, the company reported positive results from the China bridging study of KarXT for schizophrenia and promising Phase 1 data for ZL-1310 in small cell lung cancer. Zai ...
Given these trial results, there remains uncertainty about emraclidine’s future prospects and AbbVie’s ability to present a competitive alternative in the schizophrenia treatment market, particularly ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback